BioTechSign Daily Catalyst Roundup - November 21, 2026
Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →In-depth analysis of biotech catalysts, FDA timelines, dilution risk, and market signals — grounded in SEC filings and verified regulatory data.
Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, MLTX, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: UCBNV, EIKN, ZBIO, CMPX, MLTX, BAYRY. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, MLTX, VBIO, NKTR, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: BHVN, INO, EYPT, ADCT, SMMT, MLTX. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: YMAB, EYPT, SRPT, SMMT, IBRX, IDYA. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →5 FDA PDUFA target dates in December 2026: VNDA Dec 12, CORT Dec 17, MLYS Dec 22, PRAX Dec 27. Every date is sourced to a company SEC filing and verified.
Read analysis →4 FDA PDUFA target dates in November 2026: CAPR Nov 22, BBIO Nov 27, COGT Nov 30, VRTX Nov 30. Every date is sourced to a company SEC filing and verified.
Read analysis →4 FDA PDUFA target dates in January 2027: NUVB Jan 4, IBRX Jan 6, DYN Jan 21, PRAX Jan 29. Every date is sourced to a company SEC filing and verified.
Read analysis →Windward Bio Group’s approximately $175 million IPO funds WIN378 and WIN027, two respiratory-biologics candidates positioned against the Tezspire market.
Read analysis →Top BioTechSign catalyst names today: KURA, EYPT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: UCBNV, KURA, EIKN, ZBIO, CMPX, PBYI. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, PRAX, NKTR, NUVB, CAPR, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →SELLAS reached the 80th event in the Phase 3 REGAL trial of GPS in AML. The milestone unlocks final analysis, but it is not an efficacy result.
Read analysis →Top BioTechSign catalyst names today: ITCI, BGNE, DCPH, SRPT, EYPT, RNA. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: KURA, EYPT, SMMT, GRFS, NKTR, ARGX. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, ALNY. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: EYPT, SMMT, GRFS, NKTR, ARGX, NUVB. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Genmab shares doubled in three months after positive Phase 3 readouts for Rina-S, epcoritamab and petosemtamab reshaped investor expectations for its oncology pipeline.
Read analysis →Top BioTechSign catalyst names today: UCBNV, TOI, CMPX, EIKN, ZBIO, INO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
Read analysis →Roivant reported positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis. This analysis separates clinical de-risking from financing and dilution risk.
Read analysis →Arcus Biosciences completed a $250 million base offering and exercised the full underwriter option. Here is the final share count, proceeds, and dilution framework.
Read analysis →A science-first examination of the real bear cases for Moderna and Pfizer: platform economics, oncology execution, patent losses, pipeline replacement, and what investors should actually track.
Read analysis →NRx Pharmaceuticals (NRXP) received an FDA labeling review letter for preservative-free ketamine ahead of a Nov 10 GDUFA date. What's confirmed, short interest data, and dilution risk.
Read analysis →AstraZeneca and insitro announced a $1.5 billion AI-enabled target discovery partnership. What the deal structure means, who insitro is, how it fits AstraZeneca's pipeline strategy, and the implications for publicly traded AI drug discovery companies.
Read analysis →Moderna (MRNA) is up more than 500% in 2026 on the back of the first-ever positive Phase 3 result for an mRNA cancer vaccine, Nasdaq-100 index inclusion, and a full narrative reset from pandemic play to oncology platform. Here's what moved the stock and what comes next.
Read analysis →An FDA Complete Response Letter is a drug rejection that is sometimes not final. Here is how to read a CRL, assess whether resubmission is viable, and understand what the stock does next.
Read analysis →Shelf registrations and at-the-money offering programs are how most pre-revenue biotechs raise capital. Here is how to read them in SEC filings and use them as dilution risk signals.
Read analysis →A PDUFA date is the FDA's target deadline to complete review of a new drug application. Here's how to read the filing sequence, what happens at the deadline, and how to use PDUFA dates as an investment signal.
Read analysis →